BR112013014061A2 - uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla - Google Patents

uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla

Info

Publication number
BR112013014061A2
BR112013014061A2 BR112013014061A BR112013014061A BR112013014061A2 BR 112013014061 A2 BR112013014061 A2 BR 112013014061A2 BR 112013014061 A BR112013014061 A BR 112013014061A BR 112013014061 A BR112013014061 A BR 112013014061A BR 112013014061 A2 BR112013014061 A2 BR 112013014061A2
Authority
BR
Brazil
Prior art keywords
improve
laquinimod
status
life
multiple sclerosis
Prior art date
Application number
BR112013014061A
Other languages
English (en)
Portuguese (pt)
Inventor
Dan Bar-Zohar
Dina Kofler
Nora Tarcic
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013014061(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112013014061A2 publication Critical patent/BR112013014061A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013014061A 2010-12-07 2011-12-06 uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla BR112013014061A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
BR112013014061A2 true BR112013014061A2 (pt) 2016-09-13

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014061A BR112013014061A2 (pt) 2010-12-07 2011-12-06 uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla

Country Status (19)

Country Link
US (1) US20120142730A1 (enExample)
EP (1) EP2648732A4 (enExample)
JP (2) JP2013544887A (enExample)
KR (1) KR20130124518A (enExample)
CN (1) CN103260624B (enExample)
AU (2) AU2011338647A1 (enExample)
BR (1) BR112013014061A2 (enExample)
CA (1) CA2820586A1 (enExample)
CL (1) CL2013001602A1 (enExample)
EA (1) EA201390827A1 (enExample)
IL (1) IL250726A0 (enExample)
MX (1) MX2013006464A (enExample)
NZ (1) NZ611628A (enExample)
PE (1) PE20140872A1 (enExample)
PH (1) PH12013501193A1 (enExample)
SG (2) SG10201509831XA (enExample)
UA (1) UA111959C2 (enExample)
WO (1) WO2012078591A1 (enExample)
ZA (1) ZA201304237B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687512A1 (en) * 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
ME02414B (me) * 2009-07-30 2016-09-20 Teva Pharma Tretman kronove bolesti lakvinimodom
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
KR20160129093A (ko) * 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
CA2791709A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
HK1199820A1 (en) 2011-10-12 2015-07-24 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1214553A1 (zh) * 2012-09-27 2016-07-29 Teva Pharmaceutical Industries Ltd. 用於治疗神经退行性疾病的拉喹莫德和普利多匹定
CN105263325A (zh) * 2012-10-12 2016-01-20 梯瓦制药工业有限公司 用于降低多发性硬化症中丘脑损伤的拉喹莫德
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
US20140235670A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries, Ltd. Treatment of progressive forms of multiple sclerosis with laquinimod
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1225972A1 (zh) * 2013-12-20 2017-09-22 Teva Pharmaceutical Industries Ltd. 利用拉喹莫德来延缓亨廷顿氏病的进展
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
AU2015332037A1 (en) * 2014-10-16 2017-04-27 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
AU2020316640A1 (en) * 2019-07-22 2022-03-03 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
LT2653873T (lt) * 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
WO2010147665A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod

Also Published As

Publication number Publication date
CN103260624B (zh) 2015-06-03
ZA201304237B (en) 2014-08-27
AU2011338647A8 (en) 2013-09-05
EP2648732A4 (en) 2014-04-30
WO2012078591A1 (en) 2012-06-14
SG10201509831XA (en) 2015-12-30
CN103260624A (zh) 2013-08-21
PH12013501193A1 (en) 2013-07-15
JP2017095476A (ja) 2017-06-01
US20120142730A1 (en) 2012-06-07
SG190449A1 (en) 2013-07-31
AU2011338647A1 (en) 2013-07-04
EA201390827A1 (ru) 2013-12-30
CL2013001602A1 (es) 2013-10-25
WO2012078591A8 (en) 2012-08-02
PE20140872A1 (es) 2014-08-09
NZ611628A (en) 2015-06-26
UA111959C2 (uk) 2016-07-11
CA2820586A1 (en) 2012-06-14
JP2013544887A (ja) 2013-12-19
KR20130124518A (ko) 2013-11-14
IL250726A0 (en) 2017-04-30
EP2648732A1 (en) 2013-10-16
MX2013006464A (es) 2013-07-29
AU2017202055A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
BR112013014061A2 (pt) uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla
CO7000755A2 (es) Cabeza de reemplazo para un instrumento para el cuidado oral, e instrumento para el cuidado oral y su metodo de utilización
CO6910171A2 (es) Implemento de cuidado bucal y cabeza de repuesto para el mismo
EP2717922A4 (en) GENE THERAPY VECTORS FOR ADRENOLEUCODYSTROPHY AND ADRENOMYELONEUROPATHY
BR112013023928A2 (pt) componente lubrificante; lubrificante; uso do componente lubrificante; método de redução de fricção; e método de redução de desgaste
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
CO6821883A2 (es) Nuevos moduladores y métodos para su uso
BRPI1014464A2 (pt) 4-ciano-3-benzoilamino-n-fenil-benzamidas para uso no controle de pragas
HUE045656T2 (hu) PHF-tau elleni ellenanyagok és alkalmazásuk
SI3141542T1 (sl) Substituirane spojine benzaldehida in metode njihove uporabe pri povečanju oksigenacije tkiva
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
EP2773641A4 (en) BIARYLETHERSULFONAMIDES AND THEIR USE AS MEDICAMENTS
EP2686514B8 (en) Integral wear pad and method
PT2739268T (pt) Método e formulação para inalação
CL2013002601A1 (es) Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry.
FI20100196L (fi) Matalanikkelinen austeniittinen ruostumaton teräs ja teräksen käyttö
BR112014013682A2 (pt) composição para cuidado pessoal
BR302012002887S1 (pt) Configuração aplicada em garrafa para cuidado pessoal
FI20110053A0 (fi) Menetelmä laivan käyttämiseksi uudella tavalla ja monikäyttöinen laiva
BR112014010739A2 (pt) agentes terapêuticos e uso dos mesmos
BR112014014242A2 (pt) método de fortalecimento de fibras de cabelo e uso de uma composição para cabelo
BR112014014004A2 (pt) métodos e composições para redução de gordura corporal e adipócitos
BR112012028719A2 (pt) composição de tratamento de superfície dura, método para fornecer um efeito antimicrobiano a uma superfície dura e uso de uma combinação
HUE039164T2 (hu) Új benzamid-származékok és alkalmazásuk
BR112013016537A2 (pt) método para formar um laminado elastomérico e método para fabricar uma peça de vestuário de cuidados pessoais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]